Overview

DS-5565 Phase III Study for Post-herpetic Neuralgia

Status:
Completed
Trial end date:
2017-05-25
Target enrollment:
Participant gender:
Summary
Investigate the efficacy and safety of DS-5565 in subjects with Post-Herpetic Neuralgia (PHN) in comparison to placebo
Phase:
N/A
Details
Lead Sponsor:
Daiichi Sankyo Co., Ltd.
Collaborators:
Quintiles, Inc.
SRL Medisearch Inc.